Ibrutinib, a Bruton's tyrosine kinase inhibitor, a new risk factor for cryptococcosis - 07/11/20
, F. Morio c, d, J. Mahe e, P. Le Pape c, d, T. Guimard f, B. Mahe g, M. Leterrier h, M. Morrier f, F. Raffi a, b, D. Boutoille a, bBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 4 |
| Iconographies | 0 |
| Vidéos | 0 |
| Autres | 0 |
Highlights |
• | Cryptococcus neoformans infections are increasingly reported in patients receiving ibrutinib. |
• | Study of 19 cases and analysis from the international pharmacovigilance database. |
• | Cryptococcosis mostly occurred during the first six months and especially the first two months of treatment. |
• | Clinical presentation is often pulmonary. |
• | The outcome is usually favorable despite ibrutinib continuation. |
Abstract |
Purpose |
Invasive fungal diseases and especially Cryptococcus neoformans infections are increasingly reported in patients with hematological malignancies receiving ibrutinib, a Bruton's tyrosine kinase inhibitor.
Patients and method |
We reported three additional cases and reviewed 16 previous published cases together with cases from the international pharmacovigilance database.
Results |
Patients were mainly treated for chronic lymphocytic leukemia. Cryptococcosis mostly occurred during the first six months (66%) and especially the first two months (44%) of treatment. Clinical presentation is often pulmonary (68%) and the outcome is usually favorable despite ibrutinib continuation.
Conclusion |
Clinicians must be aware of this infection in patients with hematological malignancies on ibrutinib.
Le texte complet de cet article est disponible en PDF.Keywords : Chronic lymphocytic leukemia, Cryptococcosis, Ibrutinib
Plan
Vol 50 - N° 8
P. 742-745 - novembre 2020 Retour au numéro
Article précédent
- Parathyroid gland hyperplasia associated with tuberculous granulomatous inflammation manifesting as primary hyperparathyroidism
- M. Mayo-Yáñez, F.J. Lage-Fernández, L. López-Solache, P. Parente-Arias
- Infarctus splénique révélant un accès palustre à Plasmodium vivax
- S. El Aoud, C. Morin, S. Dagnet Basses, A. Selmaoui, B. Boutin, L. Thomas
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?